{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:42:08Z","timestamp":1790649728888,"version":"4.1.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>Glucocorticoids exert anti-inflammatory and immunosuppressive activities by genomic and nongenomic effects. The classic genomic effects are mediated by cytosolic glucocorticoid receptors that can upregulate the expression of anti-inflammatory proteins in the nucleus (transactivation) or repress the translocation of proinflammatory transcription factors from the cytosol into the nucleus (transrepression). The nongenomic effects are probably mediated by membrane glucocorticoid receptors. Glucocorticoid receptors are expressed also in podocytes and experimental data suggest that glucocorticoids may protect from podocyte injury. Glucocorticoids have a low therapeutic index and may exert a number of time-dependent and dose-dependent side effects. Measures to prevent or attenuate side effects include single-morning administration of short-acting glucocorticoids, dietetic counseling, increasing physical activity, frequent monitoring, and adapting the doses to the clinical conditions of the patient. Synthetic glucocorticoids, either given alone or in combination with other immunosuppressive drugs, are still the cornerstone therapy in multiple glomerular disorders. However, glucocorticoids are of little benefit in C3 glomerulopathy and may be potentially deleterious in patients with maladaptive focal glomerulosclerosis. Their efficacy depends not only on the type and severity of glomerular disease, but also on the timeliness of administration, the dosage, and the duration of treatment. Whereas an excessive use of glucocorticoids can be responsible for severe toxicity, too low a dosage and too short duration of glucocorticoid treatment can result in false steroid resistance.<\/jats:p>","DOI":"10.2215\/cjn.12991117","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T20:35:22Z","timestamp":1519418122000},"page":"815-822","source":"Crossref","is-referenced-by-count":99,"title":["Glucocorticoids in the Treatment of Glomerular Diseases"],"prefix":"10.2215","volume":"13","author":[{"given":"Claudio","family":"Ponticelli","sequence":"first","affiliation":[{"name":"Division of Nephrology, Ospedale Maggiore, Milano, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Ospedale Alessandro Manzoni, Lecco, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,2,23]]},"reference":[{"key":"B1-20230816","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1210\/jc.2008-2380","article-title":"Modified-release hydrocortisone to provide circadian cortisol profiles.","volume":"94","author":"Debono","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B2-20230816","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.cell.2014.04.038","article-title":"Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70 chaperone cycles.","volume":"157","author":"Kirschke","year":"2014","journal-title":"Cell"},{"key":"B3-20230816","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.tips.2013.07.003","article-title":"Glucocorticoid receptor signaling in health and disease.","volume":"34","author":"Kadmiel","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"B4-20230816","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1073\/pnas.0300372101","article-title":"Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects.","volume":"101","author":"Sch\u00e4cke","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B5-20230816","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/ki.2013.531","article-title":"Genetic and in vivo determinants of glucocorticoid sensitivity in relation to clinical outcome of childhood nephrotic syndrome.","volume":"85","author":"Teeninga","year":"2014","journal-title":"Kidney Int"},{"key":"B6-20230816","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1089\/gtmb.2015.0077","article-title":"Association of ACE and MDR1 gene polymorphisms with steroid resistance in children with idiopathic nephrotic syndrome.","volume":"19","author":"Dhandapani","year":"2015","journal-title":"Genet Test Mol Biomarkers"},{"key":"B7-20230816","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids: Mechanisms of action in health and disease.","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"B8-20230816","doi-asserted-by":"crossref","first-page":"F845","DOI":"10.1152\/ajprenal.00161.2010","article-title":"Dose- and time-dependent glucocorticoid receptor signaling in podocytes.","volume":"299","author":"Guess","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"B9-20230816","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s10157-011-0479-0","article-title":"Dexamethasone increases the phosphorylation of nephrin in cultured podocytes.","volume":"15","author":"Ohashi","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"B10-20230816","doi-asserted-by":"crossref","first-page":"F1375","DOI":"10.1152\/ajprenal.00020.2013","article-title":"Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS.","volume":"304","author":"Zhang","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"B11-20230816","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11010-015-2528-6","article-title":"Dexamethasone-dependent modulation of cyclic GMP synthesis in podocytes.","volume":"409","author":"Lewko","year":"2015","journal-title":"Mol Cell Biochem"},{"key":"B12-20230816","article-title":"Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): A single-blind, randomised controlled trial [published online ahead of print December 8, 2017].","author":"Isidori","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B13-20230816","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease.","volume":"176","author":"Lazarus","year":"2016","journal-title":"JAMA Intern Med"},{"key":"B14-20230816","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1176\/appi.ajp.2014.13091264","article-title":"Adverse consequences of glucocorticoid medication: Psychological, cognitive, and behavioral effects.","volume":"171","author":"Judd","year":"2014","journal-title":"Am J Psychiatry"},{"key":"B15-20230816","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.","volume":"18","author":"Kovacs","year":"2005","journal-title":"Mol Cell"},{"key":"B16-20230816","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/ndt\/gfm575","article-title":"Glomerular glucocorticoid receptor expression is reduced in late responders to steroids in adult-onset minimal change disease.","volume":"23","author":"Han","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 2","key":"B17-20230816","first-page":"1","article-title":"KDIGO clinical practice guideline for glomerulonephritis.","volume":"2","year":"2012","journal-title":"Kidney Int"},{"key":"B18-20230816","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.05000516","article-title":"Minimal change disease.","volume":"12","author":"Vivarelli","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B19-20230816","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/sj.ki.5002553","article-title":"Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations.","volume":"72","author":"Cattran","year":"2007","journal-title":"Kidney Int"},{"key":"B20-20230816","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2215\/CJN.08500815","article-title":"Anti-CD20 antibodies for idiopathic nephrotic syndrome in children.","volume":"11","author":"Ravani","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B21-20230816","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2215\/CJN.07110615","article-title":"Treatment with glucocorticoids or calcineurin inhibitors in primary FSGS.","volume":"11","author":"Laurin","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B22-20230816","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial.","volume":"15","author":"Pozzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"B23-20230816","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B24-20230816","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA nephropathy: A retrospective analysis from the VALIGA study.","volume":"26","author":"Tesar","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B25-20230816","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy.","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"B26-20230816","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial.","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"B27-20230816","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1681\/ASN.2016060647","article-title":"Corticosteroids in IgA nephropathy: Lessons from recent studies.","volume":"28","author":"Coppo","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B28-20230816","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1080\/14656566.2016.1183648","article-title":"Budesonide for the treatment of ulcerative colitis.","volume":"17","author":"Abdalla","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"B29-20230816","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): A double-blind, randomised, placebo-controlled phase 2b trial.","volume":"389","author":"Fellstr\u00f6m","year":"2017","journal-title":"Lancet"},{"key":"B30-20230816","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1681\/ASN.2011111112","article-title":"Corticosteroid therapy in IgA nephropathy.","volume":"23","author":"Lv","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B31-20230816","first-page":"CD003965","article-title":"Immunosuppressive agents for treating IgA nephropathy.","volume":"8","author":"Vecchio","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B32-20230816","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1681\/ASN.2010010117","article-title":"Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy.","volume":"21","author":"Pozzi","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B33-20230816","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/0272-6386(95)90568-5","article-title":"A review of therapeutic studies of idiopathic membranous glomerulopathy.","volume":"25","author":"Hogan","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"B34-20230816","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"key":"B35-20230816","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.","volume":"18","author":"Jha","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B36-20230816","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.ajkd.2007.05.015","article-title":"Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historic control group treated with cyclophosphamide.","volume":"50","author":"Branten","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"B37-20230816","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/ndt\/gfu306","article-title":"Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus.","volume":"30","author":"Caro","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"B38-20230816","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy.","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B39-20230816","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMra1108178","article-title":"Membranoproliferative glomerulonephritis\u2014A new look at an old entity.","volume":"366","author":"Sethi","year":"2012","journal-title":"N Engl J Med"},{"key":"B40-20230816","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: Consensus report.","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"key":"B41-20230816","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/ki.2015.227","article-title":"Effectiveness of mycophenolate mofetil in C3 glomerulonephritis.","volume":"88","author":"Rabasco","year":"2015","journal-title":"Kidney Int"},{"key":"B42-20230816","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.smim.2016.06.002","article-title":"Complement inhibition in C3 glomerulopathy.","volume":"28","author":"Nester","year":"2016","journal-title":"Semin Immunol"},{"key":"B43-20230816","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international chapel hill consensus conference nomenclature of vasculitides.","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B44-20230816","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrneph.2009.67","article-title":"ANCA-negative pauci-immune crescentic glomerulonephritis.","volume":"5","author":"Chen","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"B45-20230816","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.autrev.2014.02.007","article-title":"Rapidly progressive crescentic glomerulonephritis: Early treatment is a must.","volume":"13","author":"Moroni","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B46-20230816","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s11739-017-1636-6","article-title":"Complement blockade in ANCA-associated vasculitis: An index case, current concepts and future perspectives.","volume":"12","author":"Manenti","year":"2017","journal-title":"Intern Emerg Med"},{"key":"B47-20230816","first-page":"9","article-title":"Induction and maintenance therapy in proliferative lupus nephritis.","volume":"23","author":"Ponticelli","year":"2010","journal-title":"J Nephrol"},{"key":"B48-20230816","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.","volume":"135","author":"Illei","year":"2001","journal-title":"Ann Intern Med"},{"key":"B49-20230816","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"B50-20230816","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2215\/CJN.02271205","article-title":"A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.","volume":"1","author":"Moroni","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"B51-20230816","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.berh.2017.09.010","article-title":"Calcineurin inhibitors in systemic lupus erythematosus.","volume":"31","author":"Mok","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201805000-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:37:44Z","timestamp":1786369064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201805000-00026"}},"subtitle":["Pitfalls and Pearls"],"short-title":[],"issued":{"date-parts":[[2018,2,23]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.12991117","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,23]]}}}